• Stilla Technologies

  Participated · Series B · Feb 2020

  Stilla Technologies builds digital PCR instruments and consumables based on its Crystal Digital PCR technology, including the Nio™ platform and the recent Nio™+ 7‑color system. The Nio™+ can detect 20+ biomarkers per assay, offering a 3–4x multiplexing advantage over competitors and sitting between qPCR and NGS on cost and data density. Stilla positions its systems to fit laboratory workflows, emphasizing ease of use and automation compatibility (e.g., the Ruby Chip). The company targets applications across cancer/liquid biopsy, cell and gene therapy, infectious disease diagnostics and monitoring, epidemiology, food and environmental testing. Over 10 years of product development includes a 3‑color system in 2016, a 6‑color system in 2021, the automation‑ready Ruby Chip in 2022, and the November launch of Nio™+. Financially, Stilla closed a €26.5M Series C and employs over 80 people. Leadership and board changes were made recently following the CEO's reappointment in October, and the company cites expanded executive and board teams as part of its next chapter. Stilla Technologies develops multiplex Crystal Digital PCR solutions, most notably the naica® system—the industry's first six‑color digital PCR platform. The company targets applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla recently launched the six‑color naica® system, which it says is in high demand among researchers and clinicians. The company plans to use new financing to expand its global commercial presence and to develop its next‑generation digital PCR platform. Stilla has U.S. headquarters in Boston and European headquarters in Paris, and maintains strategic distribution and business partnerships in China. Financially, Stilla secured €31.3 million in the form of €11.3 million of convertible bonds and €20 million in loan financing. Stilla Technologies develops the Naica System, a digital PCR platform that enables precise detection and quantification of DNA mutations for research organizations in molecular biology and genetic analysis. The company was founded in 2013 at Ecole Polytechnique by Rémi Dangla, its CEO. Stilla launched the first generation of the Naica System in 2016 and generated first revenues in 2017. The Series B proceeds will be used to boost development of its solution, with a focus on high analytical performance and adding 6-color detection capabilities. The company positions its product for research organizations requiring high-precision genetic analysis. Stilla Technologies is a Paris-based life sciences company that provides a flexible digital PCR (dPCR) solution, the Naica System, for next-generation genetic tests. Founded in 2013 at École Polytechnique and led by CEO Rémi Dangla, the company leverages microfluidic innovations to make dPCR a lab commodity across the life sciences. Its core product is the Naica System; Stilla plans to launch a second-generation solution and to begin clinically validating panels to run on the system, initially focusing on oncology. The company intends to use new funding to accelerate Naica sales and expand clinical validation efforts. No operating metrics were disclosed in the article.

• Cardiologs

  Participated · Series A · Jan 2020

  Cardiologs provides a clinical decision support system that ingests readings from Holter monitors and ECG devices, uses deep learning to analyze recordings, and highlights specific episodes for cardiologist review. The company has built a database of around 1.5 million ECG recordings to train its algorithms. Its software is primarily targeted at screening for atrial fibrillation but is capable of spotting more than 100 different cardiac abnormalities. Cardiologs received CE regulatory clearance in 2016 for a deep learning–powered medical device and later attained similar certification from the U.S. Food and Drug Administration. Financially, the startup has raised a new $15 million Series A and had previously raised around $10 million, including a $6.4 million round in 2017. It plans to use the funding to double down on growth in North America and Europe and to develop new integrations and applications for its technology. Cardiologs Technologies offers the Cardiologs ECG Analysis Platform, a cloud‑based, AI‑powered web solution and API that analyzes ambulatory ECG recordings from Holter monitors, patches, smartwatches and other devices. The company has trained a neural network on more than 500,000 recordings to recognize cardiac signal patterns and assist cardiologists in screening for arrhythmias. The platform is CE‑marked in Europe for up to 100 cardiac abnormalities and received FDA clearance in July 2017 for detection of 10 significant arrhythmias, including atrial fibrillation. Scientific validation cited in the FDA submission reported a positive predictive value for AFib of 91% and sensitivity of 97%, and the company’s study was published in the European Journal of Preventive Cardiology. Cardiologs raised a $6.4M Series A and has $10M in total funding; proceeds will be dedicated to accelerating commercialization in the United States and Europe. The company plans to further extend its AI capacity beyond current ECG diagnostic claims to cover additional diagnostic capabilities.

• Sensome

  Participated · Seed · Jun 2018

  Sensome develops sensing technology that combines micro‑sensors with machine‑learning to instantly identify biological tissues upon contact and turn invasive medical tools into connected devices. The company’s first product is a guidewire called Clotild; with the new funding it will test Clotild’s clinical performance and prepare the product for market. Sensome was founded in 2014 as a spin‑off from CNRS and École Polytechnique and is based in France. The startup has partnered with Asahi Intecc on a two‑year development plan to design a new connected guidewire for ischemic stroke treatment. That collaboration includes integrating Sensome’s tissue sensor into Asahi’s Chikai guidewire to improve first‑try clot removal. The company raised Series B capital to fund clinical testing and product development. Sensome builds impedance-based micro-sensors combined with machine learning to instantly identify biological tissues, a capability the company says offers unequaled predictive reliability. The sensors are extremely thin and can be integrated into existing medical devices. Its first product, Clotild™, is a connected guidewire designed to determine clot content during ischemic stroke interventions to help physicians select optimal tools and reestablish blood flow. The company says Clotild™ targets faster, more informed stroke treatment and will undergo clinical testing. Sensome plans to bring Clotild™ to the European market and to explore additional applications of its sensing technology. Sensome recently completed a €4.6 million financing round to support these clinical and market efforts.

• DAMAE Medical

  Participated · Equity · Apr 2017

  Founded in 2014, Damae Medical’s mission is to let dermatologists observe skin at the cellular scale directly during consultations. Its core product, deepLive™, delivers instant, non-invasive cellular imaging supported by a real-time, CE-certified AI engine. Backed by more than a decade of R&D and over 250 scientific publications, deepLive™ is already installed in 120+ sites across 15+ countries, spanning hospitals and private practices. The system is used from initial diagnosis to intra-operative surgical guidance, helping thousands of patients avoid unnecessary biopsies, repeat surgeries and long waiting times. With the technology now commercially launched, the company plans to broaden access beyond early pioneer centers and make digital biopsy a routine part of dermatological care. The newly secured Series B funding strengthens its financial position and fuels this expansion. Damae Medical continues to focus on accelerating adoption, improving accuracy and reducing invasiveness in skin-cancer management.

No current team members are available.